AbbVie announced an exclusive licensing agreement with RemeGen for development of a novel bispecific antibody for advanced solid tumors in January 20264
China's Commerce Minister Wang Wentao met with executives from major multinational pharmaceutical companies including AbbVie in March 2026 to discuss the business environment for foreign pharmaceutical firms3
AbbVie is actively expanding its China operations with open positions for a Head of Development Sciences and an Executive Director of External Innovation in Shanghai25
AbbVie presented at the 44th JP Morgan Healthcare Conference in January 2026, detailing pipeline expansion strategies and announcing a $100 billion R&D investment in the US6
AbbVie announced plans to acquire a manufacturing facility in Arizona for approximately $175 million with plans to employ 200 workers6
China has expanded incentive programs for foreign pharmaceutical investment including tax breaks and preferential land use as part of efforts to reverse declining foreign direct investment3
Sources:
2. https://careers.abbvie.com/en/job/head-of-development-sciences-china-in-shanghai-shanghai-jid-26304
3. https://wixx.com/2026/03/22/china-commerce-minister-meets-pharma-executives-amid-push-for-foreign-investment/
4. https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors
5. https://careers.abbvie.com/en/job/executive-director-external-innovation-china-in-shanghai-shanghai-jid-7221
6. https://www.pharmexec.com/view/jp-morgan-2026-abbvie-advances-pipeline